Bcl-2 family members have critical roles in immune system homeostasis. Indeed, genetic loss of the pro-apoptotic molecule Bcl-2-interacting mediator of death (Bim) or loss of both Bax and Bak results in lymphadenopathy. 1, 2 Conversely, genetic loss of the anti-apoptotic molecules Bcl-2 or myeloid cell leukemia sequence 1 (Mcl-1) results in profound depletion of hematopoietic cells as well as developing thymocytes and peripheral T cells. [3] [4] [5] [6] However, the specific interactions between pro-and anti-apoptotic Bcl-2 family members and how these relationships control lymphocyte homeostasis remain unclear.
During infection, T cells engage foreign antigen resulting in a proliferative expansion of antigen-specific effector T cells. After antigen elimination, the majority of these effector T cells die by apoptosis, whereas some survive and become memory cells. 7 This culling of activated T cells is critical for restoring T-cell homeostasis, preventing autoimmunity, and promoting protective immune responses. Although initial work suggested a role for the death receptor pathway, more recent work has shown a dominant role of the mitochondrial pathway of apoptosis, governed by Bcl-2 family members, in regulating the death of activated T cells. 7, 8 Indeed, the BH3-only molecule Bim, acting through Bax/Bak, is required for the apoptosis of most effector T cells. 2, [9] [10] [11] [12] [13] Genetic ablation of Bim prevents the loss of effector CD4 þ and CD8
þ T cells and enhances protective immunity. 12, 14 However, the molecular mechanism(s) by which Bim is normally antagonized to promote effector T-cell survival remains unclear.
The expression of Bcl-2 family members is dynamically regulated in activated T cells. During T-cell activation, the levels of Bcl-2 are decreased, whereas Bcl-xL expression is increased. 13, 15, 16 However, despite the normal induction of Bcl-xL, T cell-specific genetic deletion of Bcl-xL did not exacerbate the contraction of CD4 þ or CD8 þ T cell responses, 17 suggesting that either Bcl-xL is not required for effector T-cell survival or that it is redundant with other antiapoptotic Bcl-2 family members. In the context of effector CD8 þ T-cell subpopulations, KLRG-1 hi cells have low expression of Bcl-2, whereas KLRG-1 low effector cells have high expression of Bcl-2. 13 This high level of Bcl-2 expression in KLRG-1 low cells is critical for their resistance to Bimmediated death and their survival into the memory compartment. 13 Bcl-2 levels in activated T cells are controlled by IL-7 and IL-15 signaling through STAT5, a molecule essential for effector CD8 þ T-cell survival. 18 However, the role of other anti-apoptotic Bcl-2 family members in effector T-cell apoptosis remains unclear.
Mcl-1 is another Bcl-2 family member that is highly expressed in T cells. 6, 19 Mcl-1 is critical for naive T-cell survival and Mcl-1 can efficiently bind to Bim in vitro and in vivo. 6 A recent report suggested that, at least in vitro, Mcl-1 may be an important antagonist of Bim in naive T cells. 20 Here, we investigated the role of Mcl-1 in maintaining activated T cells following lymphocytic choriomeningitis virus (LCMV) infection in mice. The loss of Mcl-1 during viral infection led to a massive loss of antigen-specific CD4 þ and CD8 þ T cells. Notably, the loss of effector T cells in Mcl-1-deleted mice was restored by the additional loss of Bax and Bak and was only partially restored by Bcl-xL overexpression, but was not restored by the additional loss of Bim. Together with our previous work on Bcl-2 being a major antagonist for Bim, 13, 21 these data show a complex specificity between anti-and pro-apoptotic Bcl-2 family members in controlling T-cell fate.
Results

Divergent expression of Mcl-1 and Bcl-2 in effector CD4
þ and CD8 þ T cells. During T-cell activation, Bcl-2 levels are decreased in both CD4 þ and CD8 þ T cells, whereas Bcl-xL levels are increased. 10, 19, 22, 23 A recent report showed that Mcl-1 levels are increased following in vitro T-cell activation, 24 although whether or not Mcl-1 levels are changed in T cells activated in vivo remains unclear. We examined expression of Mcl-1 within antigenspecific CD4 þ and CD8 þ T cells after infection with LCMV. At 8 days after infection, Mcl-1 levels were increased within LCMV-sp. CD4 þ and CD8 þ T cells, as assessed by intracellular flow cytometric analysis of MHC-tetramer þ cells (Figure 1a) . In contrast, Bcl-2 levels were decreased in both LCMV-sp. CD4 þ and CD8 þ T cells (Figure 1b) . Together, these data suggest that Mcl-1 could be a survival factor for activated T cells, particularly when Bcl-2 levels are low.
Mcl-1 is critical for survival of activated T cells in vivo. As Mcl-1 levels were increased in activated T cells, we next determined whether sustained Mcl-1 overexpression can promote effector T-cell survival. To obtain a large population of in vivo activated T cells for retroviral transduction, we injected Vb8.2 TCR Tg (VbDO) mice with staphylococcal enterotoxin B (SEB) and 24 h later, transduced purified lymph node T cells with either empty retrovirus or retroviruses overexpressing Bcl-2 or Mcl-1 and tracked the survival of transduced (Thy1.1 þ ), SEB-reactive, Vb8-bearing T cells. Similar to overexpression of Bcl-2, retroviral overexpression of Mcl-1 afforded significant protection of activated T cells after 24 h culture in vitro (Figure 2a) .
We next determined whether Mcl-1 was required for the generation of an effector T-cell response. Conventional Mcl-1-deficient embryos suffer from maturation defects at the blastomere stage along with defects in blastocyst peri-implantation. 25 Further, T-cell-specific deletion of Mcl-1 results in massive lymphopenia due to reduced survival of thymocytes and peripheral naive T cells. 6 To avoid these issues, we used a system in which Cre expression is controlled by the aIFN-inducible Mx1-promoter, to inducibly delete Mcl-1 during LCMV infection, as we have previously done to investigate the role of STAT5 in effector T-cell survival.
18 Mx1Cre-Mcl-1 f/f and Mcl-1 f/f mice were infected with LCMV and their T-cell response assessed using class I and class II MHC tetramers. At day 5 after infection, although the frequency of tetramer þ CD4 þ and CD8 þ T cells in Mx1Cre-Mcl-1 f/f mice were slightly increased, the total numbers of tetramer þ T cells in Mx1Cre-Mcl-1 f/f mice were slightly decreased when compared with control mice (Figure 2b ). This difference is likely due to a loss of total þ and CD8 þ T cells were similar to controls, consistent with our and others previous data showing that the total deletion of Bim does not increase LCMV-sp. T cells at the peak of the response. 11, 12 We again failed to detect a significant loss of Mcl-1 staining in LCMV-sp. Figure 3c ). To assess Bim deletion, we measured Bim expression within tetramer þ T cells by intracellular flow cytometry using a Bim-specific antibody. 27 Notably, we found substantial loss of Bim in CD4 þ gp61-sp and CD8 Figure 3c ). Thus, despite efficient deletion, this additional loss of Bim failed to restore either naive or LCMV-sp. CD4
þ and CD8 þ T-cell responses in mice that had inducibly deleted Mcl-1, suggesting that Mcl-1 antagonizes additional pro-apoptotic molecules in T cells. (Figure 4a) . Surprisingly, the frequency and total numbers of CD8 þ gp33-sp. T cells in Mx1Cre-Mcl-1 f/f mice were not restored by expression of ectopic Bcl-xL (Figures 4b and c) . However, the frequency and total numbers of CD4 þ gp61-sp. T cells were partially restored by Bcl-xL overexpression, but not back to control levels (Figures 4b and c f/f mice, we considered the possibility that Mcl-1 may antagonize multiple BH3-only molecules. We found that the levels of Bim, Puma, and Noxa were all expressed in naive CD4 þ and CD8 þ T cells ( Figure 5 ). Specificity of the Puma antibody was confirmed on Pumadeficient mice (Supplementary Figure 4) . Following LCMV infection, the levels of Bim and Puma were slightly decreased within effector CD4 þ and CD8 þ T cells ( Figure 5 ), whereas Noxa was increased in LCMV-sp. CD4
þ , but not CD8 (Figures 6a and b) . Further, the loss of both Bax and Bak allowed the survival and persistence effector T cells with decreased Mcl-1 expression indicating that the deletion of both pro-apoptotic effectors relieves the need of Mcl-1 (Figure 6c) .
To determine whether the restoration of Mcl-1-deleted effector T cells by the additional loss of Bax and Bak was due to increased proliferation of these cells, we injected the mice with BrdU and assessed BrdU incorporation in tetramer Mixed bone marrow (BM) chimeras reveal a cell intrinsic effect of Mcl-1 on T-cell survival. One caveat of the Mx1Cre-system is that during the course of the response, Mcl-1 is being deleted in multiple type I interferon responsive tissues and not just in T cells. 5 To circumvent this issue, we generated mixed BM chimeras using BM from CD45.1 þ T cells were enumerated on day 8 after infection. In control mice, the numbers of CD8 þ gp33-sp. and CD4 þ GP61-sp. T cells derived from CD45.2 Mcl-1 f/f mice were slightly decreased compared with those derived from CD45.1 congenics (Figure 7c ), likely because of the slightly lower CD45.2 chimerism observed in these animals (Figure 7b ). In contrast, the numbers of CD8 þ gp33-sp. and CD4 þ gp61-sp. derived from CD45.2 Mx1Cre-Mcl-1 f/f BM were decreased when compared the same cells derived from CD45.1 congenics (Figures 7c and d) . Although the chimerism was lower in this group (Figure 7b) , there was a significant loss of both CD8 þ gp33-sp. and CD4 þ gp61-sp. 
Discussion
T cells express multiple pro-and anti-apoptotic Bcl-2 family members, however, the interactions between individual Bcl-2 family members and their specific roles in maintaining T-cell homeostasis has remained unclear. Initial work, using BH3 peptides from BH3-only pro-apoptotic Bcl-2 family members indicated that Bim and Puma could bind to nearly all antiapoptotic molecules, whereas Noxa and Bad were more selective, Bad bound to Bcl-2, Bcl-xL, and Bcl-w but not A1 or Mcl-1 and Noxa had a higher affinity for Mcl-1 and A1 but not for Bcl-2, Bcl-xL, or Bcl-w. 29 These data are consistent with the function of ABT-737, a BH3-mimetic based on the BH3 domain of Bad, which targets Bcl-2, Bcl-xL, and Bcl-w, but not A1 or Mcl-1. 30 We previously showed that that Mcl-1 is a critical survival molecule for promoting naive T-cell survival in vivo 6 and others have found that Mcl-1 is critical for activated and memory T-cell survival in vitro. 24 Mcl-1 also possesses another function, to ensure appropriate mitochondrial respiration, 28 Mcl-1 is required for effector T cell survival P Tripathi et al deleted in vitro, but only when IL-7 is present. 20 However, we have failed to observe rescue of Mcl-1-deleted hematopoietic cells by the loss of Bak alone (data not shown). Nonetheless, it is possible that loss of Mcl-1 can directly lead to the spontaneous activation of both Bax and Bak in T cells. Second, it is possible that Mcl-1 inhibits a pro-apoptotic BH3-only member that functions independently of Bim. Indeed, our data show that activated T cells express Puma and Noxa in addition to Bim; therefore, it is possible that with the loss of Mcl-1, Puma, Noxa, and Bim can all facilitate the activation of Bax and Bak. 29, 35 The third possibility is that Mcl-1 acts as to 'tune' Bim-mediated death. In this scenario, Bim is largely inhibited by another anti-apoptotic Bcl-2 family member, such as Bcl-2, and Mcl-1 buffers excess Bim that is not antagonized by Bcl-2. Thus, in activated T cells, increased Mcl-1 expression may enhance resistance to death at a time when it is critical to balance pathogen clearance with immunopathology. Consistent with this concept, it has been shown that GSK-3b inhibitors can maintain Mcl-1 levels and prolong activated T-cell survival. 36 The loss of Bim failed to restore Mcl-1-deficient cells, so what normally restrains Bim in T cells? We recently showed that the loss of naive, effector, and memory CD8 þ T cells in Bcl-2-deficient or ABT-737-treated mice are largely rescued by additional Bim deficiency. 13, 21 A critical component to the sparing of effector CD8 þ T cells is the action of the cytokines IL-7 and IL-15 that act to drive STAT5-dependent expression of Bcl-2.
18 IL-4, IL-7, and IL-15 can induce an increase in Mcl-1 protein levels in activated T cells 20 and Mcl-1 levels are largely controlled post-translationally, 37 one possibility is that cytokines regulate Mcl-1's stability. However, when we cultured T cells with cycloheximide, neither IL-7 nor IL-15 significantly stabilized Mcl-1 levels within effector CD8 þ T cells (data not shown). Further, IL-7 can increase the survival of Mcl-1-deleted T cells to a similar extent as Bcl-2 overexpression and IL-7 failed to further improve survival of Bcl-2 Tg/Mcl-1-deficient effector T cells. 20 Together, these data suggest that a major survival function of cytokines is to promote the transcriptional upregulation of Bcl-2 rather than to modulate the turnover of Mcl-1.
In summary, these data suggest that critical and specific interactions between Bcl-2 family members control T-cell homeostasis. This is important because of the potential development of Bcl-2 antagonists being developed as therapeutics. As these drugs are developed for combating tumors, understanding the specificity of their interactions is crucial. One such drug, ABT-737 specifically antagonizes Bcl-2, Bcl-xL, and Bcl-w, but not A1 or Mcl-1 and is effective at tumors that express high levels of Bcl-2 or Bcl-xL, but it is ineffective against tumors expressing high levels of Mcl-1. 30, 38, 39 In tumors that do not express high levels of Bcl-2, Bcl-xL, or Bcl-w, other Bcl-2 family member antagonists may be more beneficial. However, a possible complication to these inhibitors is that they may cause lymphopenia. 21 Therefore, these inhibitors may also be exploited to target specific populations of T cells (activated effector cells) when these cells are wreaking havoc (e.g., autoimmunity). Indeed, recent studies have exploited their use in mouse models of autoimmunity with substantial benefit. 40 /BoyJ (BoyJ) were purchased from Jackson Laboratory. All animal protocols were reviewed and approved by our institutional animal care and use committees.
Virus. The Armstrong-3 strain of LCMV, described previously, 43 was grown in BHK-21 cells; the number of plaque-forming units (p.f.u.) was assayed on Vero cells as described. 43 Mice were injected intraperitoneally (i.p.) with 0.25 ml of LCMV (2 Â 10 5 p.f.u.) diluted in balanced salt solution. Determination of liver viral load was determined by plaque assay on Vero cells as described. 43 Molecular biology. Mouse Mcl-1 cDNA was purchased from Addgene (Cambridge, MA, USA) and subcloned into the retroviral plasmid MiT. 44 MiT-Bcl-2 was generated as described. 10 Retroviruses were generated by cotransfection of HEK293 with pCLEco and the MiT plasmid of interest by using calcium phosphate as described. 10 After transduction, cells were stained with various fluorescently labeled antibodies and live and dead cells were distinguished by their forward side scatter properties using a flow cytometer as described. 10 MHC tetramers. Class II MHC tetrameric staining reagents were created as described. 45, 46 The methodology for preparation of MHC class I tetramers was modified from the protocol described by Altman and co-workers 47 and were created as described previously. 12, 48 For some experiments, I-A b gp66-77 tetramers were obtained from the NIH Tetramer Core Facility. We have observed no significant difference in tracking the LCMV-sp. CD4
þ T-cell response using homemade versus NIH-generated LCMV-sp. class II tetramers.
Flow cytometry. Spleens were harvested and 10 6 cells were stained with fluorochrome-labeled antibodies (anti-CD4, anti-CD8, anti-CD44, anti-IL-7R and anti-KLRG-1) or intracellularly with antibodies against Bcl-xL (BD Transduction Labs, San Jose, CA, USA); Mcl-1 (Rockland Immunochemical, Gilbertsville, PA, USA); Bcl-2 (made in house from hybridoma 3F11); and Bim (Cell Signaling, Danvers, MA, USA), and data acquired using an LSRII flow cytometer (BD Biosciences, San Jose, CA, USA). Data were analyzed with FacsDIVA software (BD Biosciences). Antigen-specific CD4 þ T cells were identified by staining 2 Â 10 6 spleen cells with I-A b gp61-80 tetrameric staining reagents for 2 h at 37 1C, gating away from CD16/32 þ cells as described.
12 LCMV-sp. CD8 þ T cells were detected by staining 2 Â 10 6 cells/well with either D b gp33 tetrameric staining reagents for 90 min at 4 1C followed by cell surface marker staining as described. 12 Intracellular cytokine staining was performed as described. 12 Briefly, spleen cells from mice were cultured at 37 1C for 4-5 h with or without various LCMV peptides (GP61-80 10 mg/ml; GP33-41, at 1 mg/ml) and BrefeldinA at 10 mg/ml. After culture, cells were stained for cell surface markers (CD4, CD8, CD44, antibodies from BD Pharmingen, San Jose, CA, USA) for 45 min at 4 1C. Cells were then washed, fixed, and permeabilized with 0.03% saponin and stained intracellularly with PE-labeled anti-IFN-g or anti-IL-2 antibody (BD Pharmingen). A minimum of 5 Â 10 5 events were acquired on a FacsCalibur flow cytometer and analyzed using CellQuest software (BD Biosciences). /BoyJ (CD45.1 þ ) and 5 Â 10 6 cells injected intravenously into lethally irradiated (1100 Rads) BoyJ recipients and allowed to engraft for 8 weeks at which time peripheral blood analyses indicated stable engraftment of both CD45.1 and CD45.2 cell surface-positive cells at a 3 : 1 ratio. The chimeric mice were then infected as described.
Statistical analyses. Statistical analyses were performed using a Student's two-sample t-test with Minitab for Windows Software (Release 14), State College, PA, USA.
